U.S. flag An official website of the United States government

On Oct. 1, 2024, the FDA began implementing a reorganization impacting many parts of the agency. We are in the process of updating FDA.gov content to reflect these changes.

U.S. Food and Drug Administration
  1. Home
  2. Drugs
  3. News & Events for Human Drugs
  4. FDA-ISoP Public Workshop: Model Informed Drug Development (MIDD) for Oncology Products -
  1. News & Events for Human Drugs

Workshop

Event Title
FDA-ISoP Public Workshop: Model Informed Drug Development (MIDD) for Oncology Products

Co-sponsored by the:
U.S. Food & Drug Administration (FDA) and the International Society of Pharmacometrics (IsoP)

Co-Chairs: Yaning Wang: PhD, FDA, CDER, OCP
                  Amy McKee, MD, FDA, CDER, OHOP
                  Rene Bruno, PhD, Past-President, ISoP
                  Jin Y Jin, PhD, President ISoP

Under the FDA Reauthorization Act of 2017, FDA agreed, in accordance with section I of the PDUFA VI Performance Goals, Ensuring the Effectiveness of the Human Drug Review, part J, Enhancing Regulatory Decision Tools to Support Drug Development and Review, to convene a series of workshops to identify best practices for model informed drug development (MIDD).

The Food and Drug Administration (FDA) and the International Society of Pharmacometrics (IsoP) will jointly convene a workshop on model informed drug development for oncology products as part of this workshop series.

Date: February 1, 2018

Time: 8:00 a.m. to 5:20 p.m.

Location:  FDA White Oak Campus
                 10903 New Hampshire Avenue
                 Building 31, Room 1503 - Great Room B & C
                 Silver Spring, MD 20993

 

Background:

Over the past few decades, there has been extensive investment in oncology drug discovery and development.  Despite greater understanding of disease biology and drug mechanisms of action, further progress in model-informed strategies is needed to continue advancements in oncology drug development.  Innovations in clinical trial design utilizing more informative endpoints could help bring more effective treatment options to cancer patients faster by accelerating development of effective new drugs and reducing failure rates in expensive late-phase development.

As more effective and complex combination strategies and novel targets for cancer treatment evolve, exploring more informative and predictive endpoints to assess treatment response (e.g., response evaluation criteria in solid tumors- based endpoints (RECIST)) has become an active area of research.   Alternative metrics that require shorter periods of observation or provide more precise assessment of treatment effects could lead to more rapid completion of clinical trials and require fewer patients.  Promising among these alternative metrics are model-based metrics, such as those based on longitudinal continuous tumor size measurements.   Additionally, model-informed approaches can help satisfy a need to optimize dosing regimens for patients. Investigations to refine dosing regimens often occur after new drug approval and/or are driven by pharmacometric modeling approaches. There is growing interest in using model-informed approaches to help balance the risks and benefits of oncology products by identifying optimal dosing regimens and broad stakeholder engagement and discussion around this topic can be beneficial.

Workshop Objectives:

  1. Discuss “best practices” in integrating human pharmacokinetic, pharmacodynamic, efficacy, and safety data into models that best inform oncology drug development.
  2. Describe novel imaging techniques and diagnostic and predictive biomarkers that may be utilized in oncology drug development.
  3. Describe disease- and mechanism-specific early endpoints to predict long-term efficacy.
  4. Evaluate the potential to shift from traditional RECIST-based endpoints such as Overall Response Rate (ORR) and Progression Free Survival (PFS) to modified RECIST approaches (e.g. imRECIST for immunotherapies) as well as to other (model-based) tumor kinetic metrics to support early decision making in Phase 1/2 as well as in confirmatory trials.
  5. Discuss potential regulatory implications of model-informed decisions in drug development, including, model-based target identification, dose/exposure justification based on preclinical evidence, dose selection for first-in-human trials, quality by design, early clinical study design, dose finding/titration, confirmatory trials, product labeling, and post-marketing studies.

Who Should Attend:

This workshop will be open to the public. The primary audience will include pharmaceutical scientists working with small molecule development from academia, industry, and government regulatory agencies, both domestic and international.

Webcast Information:

FDA will provide a free-of-charge, live webcast of the FDA-ISOP workshop. Recordings of the webcast can be found at the following links:

  

Meeting Information:

Meeting Presentations

Session 1: Non-clinical MIDD in Oncology

Session II: Clinical MIDD in Oncology

Session III: MIDD Before and After Approval

 

 

 

 

 

 

  • List of Speakers, Moderators and Panelists
  • Speaker Bios
  • Transcript

    Speaker Bios

 

Back to Top